Erytech Pharma KOL Webinar
About The Event
The webinar will feature a presentation by Key Opinion Leaders (KOL’s) Dr. Manuel Hidalgo Medina, M.D., Ph.D. (Weill Cornell Medicine/NewYork-Presbyterian Hospital) and Dr. Marcus Noel, M.D. (Georgetown University).
Dr. Hidalgo will discuss ERYTECH’s lead product candidate eryaspase, L-asparaginase encapsulated inside donor-derived red blood cells, in the ongoing Phase 3 TRYbeCA-1 trial which has completed enrollment of 512 second-line metastatic pancreatic cancer patients at more than 120 clinical sites in Europe and the United States. The TRYbeCA-1 trial is expected to read out final results in Q4 2021. Additionally, Dr. Hidalgo will discuss the medical need and treatment options in second-line pancreatic cancer and speak on his hopes and expectations for the data read out in Q4 2021.
Dr. Noel will then discuss the view of evaluating eryaspase beyond the second-line setting. Currently, Dr. Noel is conducting in the United States an investigator sponsored Phase 1 dose-escalation trial (rESPECT) with eryaspase as part of first-line treatment for locally advanced and metastatic pancreatic cancer. Dr. Noel will share his current experience of treating patients with eryaspase in combination with chemotherapy in the first-line setting.